AUG 24·SEC EDGARLow
Schoenberg Mark sold $2.9M of URGN
Schoenberg Mark (Chief Medical Officer) sold 60,677 shares of UroGen Pharma Ltd. (URGN) at $47.05 ($2.85M total) on 2026-08-20.
StockNASDAQ · US · USDHealthcare · Biotechnology
$URGN
UroGen Pharma Ltd.
alphai earnings readsecond quarter of 2026 · AUG 5UroGen Reports $50.4 Million of ZUSDURI ® Revenue and Provides Second Quarter 2026 Financial Results and HighlightsVerdict: solidRead →
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Price · $URGNvia TradingView
AI sentiment · 7d0 articles
No enriched coverage for $URGN in the last 7 days.
Insider · 30dAll trades →
- Buys
- — 0 txs
- Sells
- $2.9M 1 txs
Schoenberg Mark1× · $2.9M
10b5-1 share of filings0%
Top stories · $URGNMore →
AUG 21·simplywall.st
UGN-103 NDA Filing for Recurrent Bladder Cancer Might Change The Case For Investing In UroGen Pharma (URGN)
UroGen Pharma (URGN) submitted a New Drug Application for UGN-103, a treatment for recurrent bladder cancer, backed by Phase 3 data. The filing could expand its RTGel-based bladder cancer franchise. Analysts project varying revenue and earnings estimates for 2029, with risks including ongoing losses and limited cash runway.
AUG 20·globes.co.il
Cancer treatment co UroGen invests $7m in Israel’s IntraGel
UroGen Pharma (URGN) invested $7M in IntraGel Therapeutics, a developer of injectable, biodegradable gels for cancer treatment. The deal includes $4M upfront and $3M for milestones. If successful, UroGen may continue development and market the treatment, expanding its oncology pipeline. UroGen reported $100M annual revenue from Jelmyto and $50M from Zusduri in the last quarter.
URGN sentiment & insider activity
Recent URGN coverage spans corporate actions, earnings and financial news.
In the last 30 days, URGN insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($2.9M). The most active reporter was Schoenberg Mark, Chief Medical Officer, with 1 filing.
What's driving URGN
Insider sale may signal reduced confidence in near-term pipeline, potentially pressuring the stock.
Potential FDA approval could unlock a new revenue stream and boost the stock.
The investment provides upfront capital and potential future milestones, likely supporting URGN's pipeline and could modestly boost its stock.
The partnership may dilute existing shareholders and ties capital to a Phase 2 trial, pressuring the share price short‑term.
The partnership expands UroGen's oncology pipeline and could unlock new revenue streams, while the $7 M investment signals confidence in the SRGel technology.
alphai scores every news story that mentions URGN with an AI model for sentiment and relevance, and aggregates insider trades from UroGen Pharma Ltd.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $URGN
Score
Schoenberg Mark sold $2.9M of URGN
Schoenberg Mark (Chief Medical Officer) sold 60,677 shares of UroGen Pharma Ltd. (URGN) at $47.05 ($2.85M total) on 2026-08-20.
1 min readUGN-103 NDA Filing for Recurrent Bladder Cancer Might Change The Case For Investing In UroGen Pharma (URGN)
UroGen Pharma (URGN) submitted a New Drug Application for UGN-103, a treatment for recurrent bladder cancer, backed by Phase 3 data. The filing could expand its RTGel-based bladder cancer franchise. Analysts project varying revenue and earnings estimates for 2029, with risks including ongoing losses and limited cash runway.
2 min read
Cancer treatment co UroGen invests $7m in Israel’s IntraGel
UroGen Pharma (URGN) invested $7M in IntraGel Therapeutics, a developer of injectable, biodegradable gels for cancer treatment. The deal includes $4M upfront and $3M for milestones. If successful, UroGen may continue development and market the treatment, expanding its oncology pipeline. UroGen reported $100M annual revenue from Jelmyto and $50M from Zusduri in the last quarter.
2 min readUroGen Pharma Stock Falls 5% After Signing Deals With IntraGel Therapeutics
UroGen Pharma's (URGN) stock fell 5% to $47.61 after signing deals with IntraGel Therapeutics. The company invested up to $7M in IntraGel's equity for Phase 2 clinical development of TumoCure, a therapy for advanced head and neck cancer, and secured an exclusive option for a worldwide license post-Phase 2 study.
1 min readUroGen Pharma Ltd.: UroGen Announces Strategic Collaboration and Investment Agreements with IntraGel to Access Biodegradable Sustained-Release Gel Platform and Expand Oncology Pipeline
UroGen Pharma (URGN) has partnered with IntraGel, gaining access to its SRGel platform for up to three oncology products and an option to license TumoCure, a treatment for advanced head and neck cancer. UroGen will invest up to $7 million in IntraGel. Early data showed TumoCure was well-tolerated and had anti-tumor activity in a small Phase 1b study.
2 min read
UroGen (URGN) Q2 2026 Earnings Call Transcript
UroGen Pharma (URGN) reported Q2 2026 revenue of $72.5 million, up from $24.2 million a year earlier, driven by ZUSDURI commercial launch. ZUSDURI revenue was $50.4 million, up 73% vs Q1 2026. JELMYTO revenue was $22.0 million. Net loss was $14.4 million. Cash was $108 million. 2026 operating expense guidance is $260-$270 million; JELMYTO revenue guidance is $97-$101 million.
7 min readTop Biotech Gainers: ATTO Debuts, AMWL Cuts Loss, PRGO Returns To The Black, URGN Hits New High
Biotech stocks rose as several companies reported updates. Attovia Therapeutics (ATTO) jumped over 28% after its Nasdaq debut at $17 and a close at $21.90. American Well (AMWL) gained about 25% after Q2 loss narrowed to $9.6M, though revenue fell to $52.0M. Perrigo (PRGO) swung to Q2 net income of $74.5M. UroGen (URGN) rose after Q2 revenue increased to $72.5M.
3 min readUroGen Pharma Ltd. (URGN): Results of Operations and Financial Condition
UroGen Pharma Ltd. (URGN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 UroGen Reports $50.4 Million of ZUSDURI ® Revenue and Provides Second Quarter 2026 Financial Results and Highlights ● ZUSDURI ® generated $50.4 million in revenue in the second quarter of 2026, representing 73% quarter-over-quarter growth ● Once issued, new U.S. pate
6 min read
UroGen Receives New U.S. Patent Allowance Expected to Provide Protection into July 2044 for ZUSDURI™ and UGN-103
UroGen Pharma (Nasdaq: URGN) said the USPTO issued a Notice of Allowance for patent application 18/784,354 covering non-surgical treatment of recurrent low-grade intermediate-risk NMIBC using a thermally gelling mitomycin composition, supported by ENVISION and ATLAS trial data. If issued, the U.S. patent would expire in July 2044 for ZUSDURI and UGN-103.
4 min readUroGen's Chief Medical Officer Sold $400,000 in Stock After a 191% Run
UroGen Pharma said its Chief Medical Officer sold about $400,000 of stock as the final trade under a 10b5-1 plan, while still holding nearly 120,000 shares. The company reported Q1 revenue up 152% to $51 million after Zusduri launch, with $29.2 million from the therapy. UroGen also said the FDA cleared UGN-501 for a planned Phase 1 study starting in Q4.
5 min read